Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
READ MORE

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

  • Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large...
READ MORE

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

  • Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing...
READ MORE

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

  • CDMO agreement for NanoFlu to support pathway to licensure
  • Expanded collaboration now includes NanoFlu and COVID-19 vaccine...
READ MORE
WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at cdmo@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.

WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at mediarelations@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.